Skip to main content


Log in

Hydroxyurea as an inhibitor of hepatitis C virus RNA replication

  • Brief Report
  • Published:
Archives of Virology Aims and scope Submit manuscript


Hepatitis C virus (HCV) is the main causative agent of chronic liver disease, which may develop into liver cirrhosis and hepatocellular carcinoma. By using a recently developed reporter assay system in which genome-length HCV RNA replicates efficiently, we found that hydroxyurea (HU), a DNA synthesis inhibitor, inhibited HCV RNA replication. Moreover, we demonstrated that the anti-HCV activity of the combination of IFN-alpha and HU was higher than that of IFN-alpha alone. These results suggest that HU may be an effective anti-HCV reagent that can be used not only singly but also in combination with IFN-alpha to treat chronic hepatitis C.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3


  1. Adams RL, Lindsay JG (1967) Hydroxyurea reversal of inhibition and use as a cell-synchronizing agent. J Biol Chem 242:1314–1317

    CAS  PubMed  Google Scholar 

  2. Bader T, Fazili J, Madhoun M, Aston C, Hughes D, Rizvi S, Seres K, Hasan M (2008) Fluvastatin inhibits hepatitis C replication in humans. Am J Gastroenterol 103:1383–1389

    Article  CAS  PubMed  Google Scholar 

  3. Belt RJ, Haas CD, Kennedy J, Taylor S (1980) Studies of hydroxyurea administered by continuous infusion: toxicity, pharmacokinetics, and cell synchronization. Cancer 46:455–462

    Article  CAS  PubMed  Google Scholar 

  4. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M (1989) Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244:359–362

    Article  CAS  PubMed  Google Scholar 

  5. Foli A, Maiocchi MA, Lisziewicz J, Lori F (2007) A checkpoint in the cell cycle progression as a therapeutic target to inhibit HIV replication. J Infect Dis 196:1409–1415

    Article  CAS  PubMed  Google Scholar 

  6. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FLJ, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975–982

    Article  CAS  PubMed  Google Scholar 

  7. Garcia M, Yu XF, Griffin DE, Moss WJ (2008) Measles virus inhibits human immunodeficiency virus type 1 reverse transcription and replication by blocking cell-cycle progression of CD4+ T lymphocytes. J Gen Virol 89:984–993

    Article  CAS  PubMed  Google Scholar 

  8. Hasford J, Baccarani M, Hehlmann R, Anseri H, Tura S, Zuffa E (1996) Interferon-alpha and hydroxyurea in early chronic myeloid leukemia: a comparative analysis of the Italian and German chronic myeloid leukemia trials with interferon-alpha. Blood 87:5384–5391

    CAS  PubMed  Google Scholar 

  9. Ikeda M, Abe K, Dansako H, Nakamura T, Naka K, Kato N (2005) Efficient replication of a full-length hepatitis C virus genome, strain O, in cell culture, and development of a luciferase reporter system. Biochem Biophys Res Commun 329:1350–1359

    Article  CAS  PubMed  Google Scholar 

  10. Ikeda M, Abe K, Yamada M, Dansako H, Naka K, Kato N (2006) Different anti-HCV profiles of statins and their potential for combination therapy with interferon. Hepatology 44:117–125

    Article  CAS  PubMed  Google Scholar 

  11. Ikeda M, Kato N (2007) Modulation of host metabolism as a target of new antivirals. Adv Drug Deliv Rev 59:1277–1289

    Article  CAS  PubMed  Google Scholar 

  12. Kuo G, Choo QL, Alter HJ, Gitnick GL, Redeker AG, Purcell RH, Miyamura T, Dienstag JL, Alter MJ, Stevens CE, Tegtmeier GE, Bonino F, Colombo WS, Lee WS, Kuo C, Berger K, Shuster JR, Overby LR, Bradley DW, Houghton M (1989) An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 244:362–364

    Article  CAS  PubMed  Google Scholar 

  13. Lori F, Malykh A, Cara A, Sun D, Weinstein JN, Lisziewicz J, Gallo RC (1994) Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science 266:801–805

    Article  CAS  PubMed  Google Scholar 

  14. Lori F, Jessen H, Lieberman J, Finzi D, Rosenberg E, Tinelli C, Walker B, Siliciano RF, Lisziewicz J (1999) Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and a protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral reservoir. J Infect Dis 180:1827–1832

    Article  CAS  PubMed  Google Scholar 

  15. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958–965

    Article  CAS  PubMed  Google Scholar 

  16. Mori K, Abe K, Dansako H, Ariumi Y, Ikeda M, Kato N (2008) New efficient replication system with hepatitis C virus genome derived from a patient with acute hepatitis C. Biochem Biophys Res Commun 371:104–109

    Article  CAS  PubMed  Google Scholar 

  17. Naka K, Ikeda M, Abe K, Dansako H, Kato N (2005) Mizoribine inhibits hepatitis C virus RNA replication: effect of combination with interferon-α. Biochem Biophys Res Commun 330:871–879

    Article  CAS  PubMed  Google Scholar 

  18. Pietschmann T, Lohmann V, Rutter G, Kurpanek K, Bartenschlager R (2001) Characterization of cell lines carrying self-replicating hepatitis C virus RNAs. J Virol 75:1252–1264

    Article  CAS  PubMed  Google Scholar 

  19. Saito I, Miyamura T, Ohbayashi A, Harada H, Katayama T, Kikuchi S, Watanabe Y, Koi S, Onji M, Ohta Y, Choo QL, Houghton M, Kuo G (1990) Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci USA 87:6547–6549

    Article  CAS  PubMed  Google Scholar 

  20. Sergerie Y, Boivin G (2008) Hydroxyurea enhances the activity of acyclovir and cidofovir against herpes simplex virus type 1 resistant strains harboring mutations in the thymidine kinase and/or the DNA polymerase genes. Antiviral Res 77:77–80

    Article  CAS  PubMed  Google Scholar 

  21. Tamura T, Matsuzaki M, Harada H, Ogawa K, Mohri H, Okubo T (1997) Upregulation of interferon-alpha receptor expression in hydroxyurea-treated leukemia cell lines. J Investig Med 45:160–167

    CAS  PubMed  Google Scholar 

  22. Tanabe Y, Sakamoto N, Enomoto N, Kurosaki M, Ueda E, Maekawa S, Yamashiro T, Nakagawa M, Chen CH, Kanazawa N, Kakinuma S, Watanabe M (2004) Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon-alpha. J Infect Dis 189:1129–1139

    Article  CAS  PubMed  Google Scholar 

  23. The Benelux CML, Group Study (1998) Randomized study on hydroxyurea alone versus hydroxyurea combined with low-dose interferon-alpha 2b for chronic myeloid leukemia. Blood 91:2713–2721

    Google Scholar 

  24. Thomas DL (2000) Hepatitis C epidemiology. Curr Top Microbiol Immunol 242:25–41

    CAS  PubMed  Google Scholar 

  25. Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K (2003) Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 38:1282–1288

    Article  CAS  PubMed  Google Scholar 

  26. Watashi K, Ishii N, Hijikata M, Inoue D, Murata T, Miyanari Y, Shimotohno K (2005) Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol Cell 19:111–122

    Article  CAS  PubMed  Google Scholar 

Download references


The authors thank Kazue Yoshihara and Yoshiko Kubushiro for their technical assistance. This work was supported by a grant for the 2008 Strategic Research Project (No. W20012) provided by Yokohama City University, Japan.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Akito Nozaki.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nozaki, A., Morimoto, M., Kondo, M. et al. Hydroxyurea as an inhibitor of hepatitis C virus RNA replication. Arch Virol 155, 601–605 (2010).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: